** Shares of Australia's Telix Pharmaceuticals TLX.AX rise as much as 6.3% to A$11.99, posting their biggest intraday pct gain in nearly two months

** Stock touches its highest level since December-end

** Biopharma co says the Chinese National Medical Products Administration (NMPA) has accepted New Drug Application (NDA) for its prostate cancer diagnosis agent, Illuccix

** Says NDA submitted in association with partner Grand Pharmaceutical Group 0512.HK in Greater China region

** Illuccix used as a scanning agent to detect prostate cancer in body

** TLX among top gainers on the broader Australian benchmark index .AXJO, which is down 0.5%

** TLX up 4.6% YTD after a 54.5% drop in 2025

(Reporting by Aamir Sheik Khalid in Bengaluru)

((Aamir.SheikKhalid@thomsonreuters.com))